Skip Navigation

Lotus signs exclusive licensing and commercialization agreement with PharmaMar for Zepzelca® (lurbinectedin) in Taiwan

11 November 2021

Lotus Pharmaceutical (1795:TT), a multinational pharmaceutical company, today announced that it has signed a licensing agreement with Pharma Mar S.A. (MSE: PHM, “PharmaMar”) for commercializing the anticancer drug Zepzelca® (lurbinectedin) in Taiwan. Under this partnership, Lotus will be responsible for pursuing the marketing approval in Taiwan and have the right to market the product exclusively upon approval.  

Zepzelca® (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. It is the first NCE cancer drug that Lotus licenses in from the originator aiming to further penetrate the lung cancer market in Taiwan along with its existing portfolio.

Petar Vazharov, Chief Executive Officer of Lotus, said, “Lung cancer has been among the top cause of death in Taiwan for decades. We are very honored to have this opportunity partnering with PharmaMar to offer the patients in Taiwan access to innovative drug, which is aligned with our key focused therapeutic area and strengthens our oncology portfolio.”

Luis Mora, General Manager of PharmaMar's Oncology and Virology Business Units, also commented, “We are very pleased to sign this new agreement with Lotus, which will allow, if approved, to bring lurbinectedin to all patients in Taiwan who need it.”